Literature DB >> 1724550

Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice.

A Polak-Wyss1.   

Abstract

Prophylactic treatment with human granulocyte colony-stimulating factor (hG-CSF) affords significant protection against systemic aspergillosis or pulmonary aspergillosis in neutropenic (cyclophosphamide-treated) mice but not in cortisone-treated animals. Cryptococcosis does not respond to hG-CSF therapy. Our data show that granulocytes play an important role in the immune defense against aspergillosis, but not against cryptococcosis. Combined treatment using hG-CSF and conventional antimycotics shows a significant beneficial effect in systemic or pulmonary aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724550     DOI: 10.1111/j.1439-0507.1991.tb00645.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  14 in total

1.  A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients.

Authors:  A Böhme; G Just-Nübling; L Bergmann; P M Shah; W Stille; D Hoelzer
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

Review 2.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

3.  Effects of granulocyte and granulocyte-macrophage colony-stimulating factors in a neutropenic murine model of trichosporonosis.

Authors:  H Muranaka; M Suga; K Nakagawa; K Sato; Y Gushima; M Ando
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

Review 4.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Necessary and sufficient role for T helper cells to prevent fungal dissemination in allergic lung disease.

Authors:  Paul C Porter; Luz Roberts; Anna Fields; Morgan Knight; Yuping Qian; George L Delclos; Shuhua Han; Farrah Kheradmand; David B Corry
Journal:  Infect Immun       Date:  2011-08-29       Impact factor: 3.441

6.  Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis.

Authors:  J M Smith; C M Tang; S Van Noorden; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

8.  Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

Authors:  Andriani C Patera; Frederick Menzel; Craig Jackson; Joan K Brieland; Judy Halpern; Roberta Hare; Anthony Cacciapuoti; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

Review 10.  New advances in invasive aspergillosis immunobiology leading the way towards personalized therapeutic approaches.

Authors:  Joshua J Obar; Tobias M Hohl; Robert A Cramer
Journal:  Cytokine       Date:  2016-05-30       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.